港股異動 | 輔助生殖上游龍頭貝康醫療漲7.8% 券商稱其核心產品將穩步放量
格隆匯2月6日丨輔助生殖概念股集體上漲,貝康醫療(2170.HK)漲7.8%,報6.36港元,總市值17億港元,股價創12個月新高。國家醫保局近日表示,將逐步把適宜的分娩鎮痛和輔助生殖技術項目納入醫保基金支付範圍,並鼓勵中醫醫院開設優生優育門診,提供不孕不育診療服務。國金證券認為若未來部分地區逐步將輔助生殖納入醫保,國內輔助生殖行業的滲透率有望進一步提升。中信證券此前發研報稱,貝康醫療是我國輔助生殖上游龍頭產業,在PGT產品領域的競爭壁壘、全管線的戰略佈局和長期增長潛力,予公司目標價至12港元,維持“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.